BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27584024)

  • 21. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Salvage lymph node dissection for nodal recurrent prostate cancer].
    Stolzenbach LF; Knipper S; Maurer T
    Aktuelle Urol; 2020 Jun; 51(3):258-264. PubMed ID: 32219775
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?
    Pisano F; Gaya JM; Breda A; Palou J
    World J Urol; 2019 Aug; 37(8):1551-1556. PubMed ID: 31214766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Value of
    Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
    Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC; Eiberger AK; Volegova-Neher N; Henne K; Krauss T; Grosu AL; Jilg CA
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature.
    Ploussard G; Almeras C; Briganti A; Giannarini G; Hennequin C; Ost P; Renard-Penna R; Salin A; Lebret T; Villers A; Soulié M; de la Taille A; Flamand V
    J Urol; 2015 Oct; 194(4):983-8. PubMed ID: 25963190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of
    Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer.
    Quhal F; Bryniarski P; Rivas JG; Gandaglia G; Shariat SF; Rajwa P
    Curr Opin Urol; 2023 Jul; 33(4):269-273. PubMed ID: 37166270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Ploussard G; Gandaglia G; Borgmann H; de Visschere P; Heidegger I; Kretschmer A; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; van den Bergh R; Ost P; Briganti A;
    Eur Urol; 2019 Oct; 76(4):493-504. PubMed ID: 30391078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence.
    Peeters C; Ponette D; van Poppel H
    Urol Int; 2017; 98(3):367-369. PubMed ID: 25228162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
    Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
    BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage lymph node dissection in hormone-naïve men: How effective is surgery?
    Hanske J; Ostholt J; Roghmann F; Müller G; Braun K; Gomez B; von Landenberg N; von Bodman C; Palisaar RJ; Liermann D; Noldus J; Brock M
    Urol Oncol; 2019 Nov; 37(11):812.e17-812.e24. PubMed ID: 31327750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection.
    Osmonov DK; Aksenov AV; Trick D; Naumann CM; Hamann MF; Faddan AA; Jünemann KP
    BMC Urol; 2016 Sep; 16(1):56. PubMed ID: 27601051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. See the unseen: Mesorectal lymph node metastases in prostate cancer.
    Hijazi S; Meller B; Leitsmann C; Strauss A; Ritter C; Lotz J; Meller J; Trojan L; Sahlmann CO
    Prostate; 2016 Jun; 76(8):776-80. PubMed ID: 26880517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.
    Jilg CA; Rischke HC; Reske SN; Henne K; Grosu AL; Weber W; Drendel V; Schwardt M; Jandausch A; Schultze-Seemann W
    J Urol; 2012 Dec; 188(6):2190-7. PubMed ID: 23083862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.